MARCOS COTA: Open Payments
NPI 1073287298 · RENO, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$720 in 15 payments from 10 companies in 2025. Trend: 2023 $400 · 2024 $793 · 2025 $720
Food & beverage: $720
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 6 | $201 |
| Novo Nordisk Inc | 1 | $117 |
| Teva Pharmaceuticals USA, Inc. | 1 | $114 |
| ViiV Healthcare Company | 1 | $96 |
| AstraZeneca Pharmaceuticals LP | 1 | $96 |
| Alkermes, Inc. | 1 | $24 |
| SANOFI PASTEUR INC. | 1 | $21 |
| Lilly USA, LLC | 1 | $19 |
| Merck Sharp & Dohme LLC | 1 | $18 |
| GlaxoSmithKline, LLC. | 1 | $15 |
Products named: VRAYLAR, Wegovy, AUSTEDO XR, APRETUDE, FARXIGA, VIVITROL, BEYFORTUS, MOUNJARO.
Industry payments across NV — which companies pay providers there.
